Clinical Research

GS -US-380-4030 (HIV)

The primary objective of this study is to evaluate the efficacy of switching from a regimen of either dolutegravir (DTG) and emtricitabine /tenofovir alafenamide (F/TAF) or DTG and emtricitabine/tenofovir disoproxil fumarate (F/TDF) to a fixed dose combination (FDC) of bictegravir/emtricitabine/tenofovir alafenamide (B/F/TAF) versus DTG+F/TAF in virologically suppressed HIV-1 infected adults with or without antiretroviral (ARV) resistance.

For more information on this clinical trail Click Here

The office of Dr. Joseph Gathe, Jr. is pleased to offer both in office visits as well as telemedicine services.

(Mask donated to the staff by designer David Peck. Thank you)

Please call for more details
713 526 9821

Download Zoom which will be our telemedicine partner.

4900 Fannin st.
Houston Tx. 77004
713 526 9821

Copyright © 2020 - All rights reserved - Website Hosting and Maintenance provided By JRS